Goodwin, a leading Global 50 law firm, announced today that Roger Cohen has joined the firm’s Life Sciences and Private Equity practices as a partner in the firm’s New York office.
Cohen specializes in representing health care, life sciences and health care IT clients, and investors in such companies, in a wide array of regulatory matters. He has particular expertise in health care fraud and abuse, HIPAA and related privacy and data security issues, Medicare and Medicaid rules and regulations, reimbursement matters, telemedicine, and government investigations and enforcement actions, including litigation under the False Claims Act. Cohen also advises clients on compliance matters in the context of health care transactions.
“The health care IT and services sector is rapidly evolving with varying levels of legal and regulatory complexity,” said Mitch Bloom, Chair of Goodwin’s Life Sciences Practice. “Roger’s extensive experience in this dynamic sector and his wide-ranging knowledge of the related issues will benefit Goodwin’s established and start-up health care clients, as well as our private equity clients. We are delighted that Roger has chosen to join the Goodwin platform.”
“Our work for private equity clients in the health care sector is robust and expanding,” said AJ Weidhaas, Co-Chair of the firm’s Private Equity Practice. “Roger’s addition will enhance our ability to provide these clients end-to-end service both in their transactions and for their portfolio companies.”
Cohen joins Goodwin from Proskauer, where he practiced in its health care group. He received his J.D. cum laude from Fordham University School of Law and his bachelor’s degree from the University of Michigan. Cohen is recognized as a leading lawyer by The Legal 500 United States and was named a “Rising Star” by both Law360 and Super Lawyers.
He can be reached at firstname.lastname@example.org or 212.459.7002.
Goodwin’s Life Sciences Practice is deeply experienced in corporate governance, financing and M&A transactions, collaborations and licensing, regulatory matters, and intellectual property law. It was recently named “Practice Group of the Year” by Law360, which called Goodwin “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” Goodwin has been consistently recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year,” including in 2017.
The firm’s internationally recognized Private Equity Practice focuses on buyouts, recapitalizations, growth equity investments, and portfolio company transactions in the United States and internationally with a leading position in the U.S. middle markets and growth equity. With a team of over 100 lawyers, the practice covers the full life cycle of clients’ investments – from fund formation to exit and everything in between.